Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31347392 | 0.82 | TDP1 (0.46) | CYP3A4TDP1DRD1ESR1ESR2 | |
| SCHEMBL10718341 | 0.82 | TDP1 (0.46) | CYP3A4TDP1DRD1ESR1ESR2 | |
| SCHEMBL2850053 | 0.78 | TDP1 (0.42) | CYP3A4TDP1DRD1ESR1ESR2 | |
| SCHEMBL17124497 | 0.78 | TDP1 (0.42) | CYP3A4TDP1DRD1ESR1ESR2 | |
| Acetic Acid SCHEMBL31362943 | 0.76 | ALDH1A1 (0.41) | CYP3A4TDP1DRD1ESR1ESR2 | |
| SCHEMBL15698213 | 0.74 | CYP3A4 (0.46) | CYP3A4TDP1DRD1ESR1ESR2 | |
| SCHEMBL30085602 | 0.74 | TDP1 (0.46) | CYP3A4TDP1DRD1ESR1ESR2 | |
| SCHEMBL10792614 | 0.74 | TDP1 (0.46) | CYP3A4TDP1DRD1ESR1ESR2 | |
| Bromide SCHEMBL31398207 | 0.74 | CYP3A4 (0.46) | CYP3A4TDP1DRD1ESR1ESR2 | |
| SCHEMBL9007722 | 0.73 | CYP3A4 (0.41) | CYP3A4TDP1DRD1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673891-B2 | Aminopyrazine derivative and medicine | NIPPON SHINYAKU CO., LTD. (JP) | 2014-03-18 | — | — | US | disclosed |
| US-8586591-B2 | Aminopyrazine derivative and medicine | NIPPON SHINYAKU CO., LTD. (JP) | 2013-11-19 | — | — | US | disclosed |
| US-20110288065-A1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO., LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288065-A1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | MC2R, CNR1, NPY2R | CYP3A4 315/4885TDP1 3567/4885DRD1 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.